Skip to content

Pharmacokinetics of 0.25% levobupivacaine with clonidine following caudal epidural administration in children

A non-randomised single group study on the pharmokinetics of 0.25% levobupivacaine with clonidine administered caudally in children undergoing elective sub-umbilical surgical procedures for which caudal epidural analgesia is indicated

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12609000126213
Enrollment
65
Registered
2009-02-20
Start date
2009-02-20
Completion date
2009-10-30
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of this study is to determine how clonidine affects the absorption of levobupivacaine in children having caudal anaesthesia for sub-umbilical surgery. Our study hypothesis is that the absorption of levobupivacaine will be affected when administered in conjunction with clonidine via the caudal route.

Interventions

Participants will recieve 0.25% levobupivacaine in a volume to be determined by the attending anaesthetist with clonidine 2mcg/mL, via the caudal route, under general anaesthesia

Sponsors

Royal Children's Hospital
Lead SponsorHospital

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
0 to 18 Years
Healthy volunteers
No

Inclusion criteria

Inclusion criteria: 1. Children aged under 18 years. 2. Subumbilical surgery planned. 3. Caudal analgesia with levobupivacaine and clonidine regarded as acceptable standard of care by treating anaesthetist (or by independent anaesthetist where conflict of interest arises between research and treating anaesthetist)

Exclusion criteria

Exclusion criteria: 1. Caudal analgesia refused by parent/guardian. 2. Allergy to levobupivacaine/drug solution excipients. 3. Administration of levobupivacaine or clonidine via any route in 72 hours prior to, or any extra administration during, the study period.

Outcome results

None listed

Source: ANZCTR · Data processed: Aug 31, 2026